Equillium, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2018; filed November 15, 2018. Equillium is an early-stage biotechnology company developing EQ001 (itolizumab) for severe immuno-inflammatory diseases. It had no product revenue and had not yet begun its own patient clinical trial. The 2017 comparisons cover the company’s early operating period and are not full-year comparisons.
Financial results and liquidity
| Metric | Three months ended September 30, 2018 | Nine months ended September 30, 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $1.22 million | $2.43 million |
| General and administrative expense | $1.00 million | $1.96 million |
| Net loss | $4.92 million | $8.26 million |
| Net loss per share, basic and diluted | $0.44 | $0.76 |
| Cash used in operating activities | Not presented for the quarter | $3.70 million |
- Third-quarter 2018 net loss was $0.14 million in the corresponding 2017 quarter. Nine-month 2018 net loss was $8.26 million versus $1.16 million from inception through September 30, 2017. Management attributed expense growth chiefly to higher personnel, consulting, preclinical and operating costs.
- Interest expense was $1.22 million for the quarter and $2.33 million for the nine months, primarily non-cash accretion related to convertible notes. The Biocon anti-dilution right’s fair-value expense was $1.50 million and $1.60 million, respectively. These items increased reported losses and are not equivalent to cash operating costs.
- At September 30, cash and cash equivalents were $4.98 million; current assets were $5.06 million and current liabilities $2.68 million. Total assets were $6.42 million. Convertible notes, including accrued discount and related-party notes, had a balance-sheet carrying amount of approximately $11.60 million. The company had a $10.52 million accumulated deficit. Profit margins are not meaningful because there was no revenue.
- Nine-month investing cash outflow was $25,381; financing cash inflow was $1.60 million, and cash declined by $2.12 million.
Material changes and subsequent events
- In October 2018, Equillium completed an IPO at $14 per share. The filing reports approximately $58.7 million in net proceeds from the initial 4.67 million shares and approximately $5.8 million from the underwriters’ additional 445,097 shares sold in November. The filing’s use-of-proceeds section reports approximately $64.5 million net proceeds in total.
- In connection with the IPO, convertible notes converted into 878,834 common shares, and 228,060 shares were issued to Biocon to satisfy the anti-dilution right. The company expected to record an additional approximately $0.8 million expense in the fourth quarter for the Biocon settlement.
- The company implemented a 1-for-8.62 forward stock split in October; reported share and per-share figures reflect the split. It reported 17,376,236 common shares outstanding as of November 13, 2018.
Outlook, risks and contingencies
- Management expected cash at September 30, together with IPO proceeds, to fund currently planned operations for at least 24 months. This estimate depends on assumptions that may change; the company said it would need substantial additional capital to complete EQ001 development and expected losses and negative operating cash flows to continue for years.
- Planned development included a Phase 1b/2 aGVHD trial in early 2019, with top-line data from its Phase 1b portion expected within 12 months of initiation; a Phase 2 cGVHD trial and a severe-asthma proof-of-concept trial were planned for the first half of 2019. Timelines and costs were uncertain, and success was not assured.
- Equillium’s principal asset was EQ001, licensed for the United States and Canada from Biocon. Risks include clinical, regulatory, manufacturing and enrollment uncertainty; dependence on Biocon and other third parties; competition; and the possibility of needing further financing on unfavorable terms. EQ001 had not been approved by the FDA.
- A significant regulatory risk concerns the antibody’s Cuban-origin intellectual property. The company relied on an OFAC general license for development activities, but OFAC had not confirmed its applicability to EQ001. Equillium had sought interpretive guidance and planned to apply for a specific license; denial could prevent EQ001 development and commercialization.
- The Biocon license includes up to $30 million in regulatory milestones, up to $565 million in sales milestones, and tiered royalties ranging from mid-single digits to sub-teen double digits. No milestone or royalty payments had been made or received as of the filing.
- Management reported no legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls at September 30, 2018. The filing checked “No” to whether the company had filed all required Exchange Act reports during the preceding 12 months.
Important facts for investors to verify
- Whether the planned EQ001 trials began on schedule and what their enrollment, safety and efficacy results show.
- OFAC’s determination and any specific license covering EQ001-related activities.
- Actual cash use and runway compared with management’s 24-month estimate, including the impact of clinical development and public-company costs.
- Biocon supply arrangements, license milestones and royalties, and the terms and accounting for the anti-dilution settlement and note conversion.
- The final IPO proceeds and share count, and the potential effect of future equity issuance and expiring lock-up restrictions.